Latest Ratios: P/E Ratio -4.0x · EV/EBITDA N/A · ROE -73.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $451M | $329M | $408M | $351M | $314M | $496M | — | — |
| Enterprise Value | $409M | $287M | $395M | $330M | $214M | $348M | — | — |
| P/E Ratio → | -3.99 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.10 | 2.40 | 2.69 | 1.55 | 1.61 | 3.26 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -73.5% | -73.5% | -46.0% | -36.3% | -33.8% | -41.1% | -88.6% | -78.7% |
| ROA | -60.3% | -60.3% | -39.7% | -31.9% | -30.6% | -38.7% | -75.1% | -65.3% |
| ROIC | -72.4% | -72.4% | -42.0% | -42.6% | -91.3% | -851.2% | -10124.3% | — |
| ROCE | -70.8% | -70.8% | -46.9% | -37.3% | -32.9% | -41.0% | -88.2% | -78.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.12 | 0.09 | 0.11 | 0.01 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.31 | -0.09 | -0.10 | -0.51 | -0.97 | -0.90 | -1.05 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -2711.54 | -7402.00 | -4839.00 |
Net cash position: cash ($60M) exceeds total debt ($17M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.15 | 8.15 | 10.77 | 18.76 | 18.81 | 20.90 | 6.94 | 5.42 |
| Quick Ratio | 8.15 | 8.15 | 10.77 | 18.76 | 18.81 | 20.90 | 6.94 | 5.42 |
| Cash Ratio | 7.85 | 7.85 | 10.13 | 18.30 | 18.06 | 20.27 | 6.54 | 5.28 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $60M | $50M | $40M | $30M | $29M | $29M | $2.9B |
Insufficient clinical cash runway
According to current market data, AURA trades at a price-to-book ratio of 3.08, which reflects investor anticipation of the VDC platform's potential rather than any underlying earnings, as the company remains pre-revenue and continues to generate negative net income across all reported historical periods.
The valuation multiple appears to be driven by the binary potential of the CoMpass trial rather than fundamental financial metrics. Investors should monitor whether this premium holds as the company approaches critical data readouts, as any delay in clinical milestones may lead to significant multiple compression.
Based on reported financial statements, AURA's return on invested capital has deteriorated to -39.0% in 2026Q1, illustrating the heavy capital consumption required to advance the VDC platform through late-stage clinical trials without the benefit of offsetting commercial revenue streams.
The consistent decline in ROIC suggests that the company is effectively destroying capital in the short term to fund long-term R&D objectives. This trend is typical for pre-revenue biotech firms, but it warrants further investigation into whether the efficiency of capital deployment improves as the company nears potential commercialization.
As indicated by historical filings, the company's days payable outstanding has fluctuated significantly, reaching 677 days in 2026Q1, which suggests that AURA is leveraging its vendor relationships to manage cash outflows during the intensive Phase 3 clinical trial period.
The high DPO reflects a strategic reliance on extended payment terms with CROs and manufacturing partners to preserve liquidity. This approach appears to be a necessary survival mechanism, though it may limit the company's flexibility if vendors demand more favorable payment terms in the future.
According to recent quarterly data, the current ratio has compressed from 21.97 in 2024Q1 to 7.09 in 2026Q1, signaling that the company's liquidity position is tightening as the cash burn associated with the CoMpass trial accelerates relative to the remaining cash reserves.
While a current ratio of 7.09 remains technically robust, the rapid downward trend indicates that the company is consuming its liquid assets at an unsustainable pace. This trajectory suggests that management may need to secure additional financing within the next few quarters to maintain operational continuity.
Financial analysts frequently misapply traditional P/E and EBITDA multiples to AURA, which obscures the reality that these metrics are irrelevant for a pre-revenue biotech firm where the primary value driver is the clinical success of the VDC platform rather than current operational profitability.
Using earnings-based ratios for a company in the clinical development stage leads to misleading conclusions about its financial health. Instead, investors should focus on the cash runway duration and the probability-weighted net present value of the clinical pipeline to better assess the company's true economic potential.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AURA stock.
Aura Biosciences, Inc.'s current P/E ratio is -4.0x. This places it at the 50th percentile of its historical range.
Aura Biosciences, Inc.'s return on equity (ROE) is -73.5%. The historical average is -56.8%.
Based on historical data, Aura Biosciences, Inc. is trading at a P/E of -4.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.